Introduction
Currently, bladder cancer (BC) is the 4th most common cancer in males and the 11th most common cancer in females, with an incidence of 68800 new cases per year in the USA alone. 1 Despite significant advances in treatment, BC continues to be an extremely common disease with high mortality. It has been shown that widespread screening could decrease mortality from the disease. 2 The current standards of care for detecting and monitoring BC are cystoscopy, voided urine cytology and imaging. 3 Given the cost and invasive nature of such diagnostic techniques, looking for sensitive and specific biomarkers, as well as noninvasive early detection tests for BC, becomes an urgent subject. 4 Metabolomics, as a combination of spectroscopic measurement of biological samples with multivariate data analysis, has been employed extensively to address the diagnosis and evaluation of cancer patients, and to identify potential biomarkers. [5] [6] [7] [8] Another related term "metabonomics" was initially defined as "the quantitative measurement of the multi-parametric metabolic response of living systems to pathophysiological stimuli or genetic modifications". 9 The definition of metabolomics is evolving rapidly towards its "brother"-metabonomics. Metabonomics/ metabolomics can expect much more development and will probably converge, given enough time. 10 Several works have been performed to explore metabolic profiles of BC patients and healthy subjects. For example, Issaq et al. utilized liquid chromatography-mass spectrometry (LC-MS)-based metabolomics to analyze urinary samples from BC patients, identifying 46 of 48 healthy subjects and 40 of 41 BC patients. 11 Patel et al. used gas chromatography-mass spectrometry (GC-MS)-based metabolomics to accurately distinguish urine samples of BC patients from those of healthy subjects. 12 These previous works were primarily focused on the early diagnosis of BC patients. Both the metabolite variations and altered metabolic pathways remain to be addressed, these aspects are associated with the pathogenic process of BC. Elucidation of the association between metabolic profiles and BC would open a new potential avenue in the diagnosis and surveillance of the disease.
In this present work, we performed 1 H nuclear magnetic resonance (NMR)-based metabolomic analysis on serum samples from: (a) low-grade BC patients (LBC), high-grade BC patients (HBC); (b) pre-and post-transurethral resection of bladder tumor patients (TURBT); (c) urinary tract calculi patients with the similar clinic sign of hematuria as BC patients; (d) healthy subjects. The objectives were: (i) to depict serum metabolic characteristics of BC patients compared with those of both healthy subjects and calculi patients; (ii) to assess altered metabolic pathways associated with the pathogenic process of BC, and to exploit potential biomarkers for the diagnosis and surveillance of BC patients on the basis of blood samples. Our work identifies characteristic metabolites in the serum, and reveals disturbed metabolic pathways of aromatic amino acids, glycolysis and citrate cycle, as well as lipogenesis metabolism in BC patients. Our results offer valuable information for noninvasive diagnosis of BC.
Bladder cancer (BC) is one of the most common cancers and has a high mortality rate. However, both metabolite variations and metabolic pathways related to the pathogenic process of BC remain to be addressed, such results might contribute to early detection of the disease. 1 H nuclear magnetic resonance (NMR)-based metabolomics was applied to identify differences of serum metabolic profiles among BC, calculi patients and healthy subjects. Serum metabolic profiles of BC patients are distinctly different from those of calculi and healthy subjects. Compared with those from healthy subjects, serum samples from BC patients show decreased levels of isoleucine/leucine, tyrosine, lactate, glycine, citrate, as well as increased levels of lipids and glucose. The results reveal disturbed metabolic pathways of aromatic amino acids, glycolysis and citrate cycle, as well as lipogenesis metabolism in BC patients. Our work will be of potential benefit to understanding the pathogenic process of BC and will offer valuable information for noninvasive diagnosis of the disease. 
Experimental

Reagents and chemicals
Deuterium oxide (D2O, 99.9% in D) was purchased from Cambridge Isotope Laboratories, Inc. Sodium dihydrogen phosphate dihydrate (NaH2PO4·2H2O) and disodium hydrogen phosphate dodecahydrate (Na2HPO4·12H2O) are analytical grade reagents purchased from Sinopharm Chemical Regent Co.
Collection of serum samples
The study protocol was approved by the Ethics Committee of Shanghai Jiao Tong University School of Medicine. All the diagnoses of BC patients were confirmed by cystoscopy examination. Blood samples were obtained from 22 cases of HBC patients (the HBC group), from 17 cases of LBC patients (the LBC group), and from 28 urinary tract calculi patients (the calculi group) from Renji Hospital of Shanghai Jiaotong University, China.
In order to compare the metabolic characteristics between pre-TURBT and post-TURBT patients, we used another group of 20 BC patients (including LBC and HBC), from whom blood samples were also obtained before and about three months after TURBT, respectively. Control blood samples were obtained from 25 healthy subjects after detailed clinical questioning (the healthy group). Table 1 outlines the characteristics of the subjects studied in this work. All subjects have been free from medications for at least 3 months. About 5 mL of blood was drawn from participants who had fasted for 12 h; the blood was clotted for 1 h at room temperature. Then serum was separated after centrifugation at 1000g for 10 min at 4 C. Aliquots of sera were stored at -80 C until NMR analysis. 1 
Preparation of serum samples and acquisition of
H NMR spectral data
Prior to NMR analysis, serum samples were thawed. Then, 240 μL of aliquots were mixed with 300 μL of phosphate buffer (0.2 M Na2HPO4/0.2 M NaH2PO4, pH 7.4) to minimize variations in the pH value. The serum samples were centrifuged at 12000g for 10 min at 4 C to separate any precipitate. Thereafter, 500 μL of the resulting supernatants were transformed into 5 mm NMR tubes containing 60 μL of D2O (as a field-frequency lock). All NMR spectra were recorded at 25 C on a Varian Unity INOVA 600 NMR spectrometer equipped with a triple resonance probe and a z-axis pulsed field gradient. One-dimensional spin-echo spectra were recorded using the CPMG (Carr-Purcell-Meiboom-Gill) sequence of D-[-90 -(τ-180 -τ)n-ACQ], where a fixed total spin-spin relaxation delay 2nτ of 120 ms was used to distinguish the broad NMR signals from slowly tumbling molecules such as proteins and to retain those from low-molecular weight compounds and some lipid components.
Typically Resonance assignments of metabolites in the serum were performed based on chemical shifts reported in the literature 5, 13 and on 2D 1 H-1 H COSY and TOCSY spectra. Both 2D NMR spectra were recorded with a relaxation delay of 1.0 s and a water signal suppression of 1.5 s. Spectral widths of 8000 Hz were used for 1 H dimensions. For each 2D spectrum, 512 increments with 64 transients per increment were collected and extended to 4000 data points using linear prediction and zero-filling approaches. The TOCSY experiment made use of a MLEV-17 spin-lock scheme for 1 H-1 H transfers with a mixing time of 80 ms at the spin-lock strength of 8000 Hz.
Multivariate pattern recognition and statistical analysis
NMR data were reduced to 3000 integrated regions with a width of 0.003 ppm, corresponding to the region of δ 9.5 to 0.5. For NMR spectra recorded on serum samples, the region of about δ 5.2 -4.6 was removed to eliminate artifacts related to the residual water resonance. Each data point was normalized to the sum of its row to compensate for variation in sample volumes.
Prior to multivariate statistics, the data were mean-centered and pareto-scaled. The unsupervised principal component analysis (PCA) was first used in all serum samples to check general separation and to identify the outliers. Then, supervised orthogonal partial least-squares-discriminant analyses (OPLS-DA) were performed using SIMCA-P + V12.0 software package (Umetrics, Umea, Sweden). To guard against model overfitting, we validated the supervised models with a 200 times permutation test. 14 Statistical analysis was performed using the SPSS software (Ver. 11.0, SPSS Inc., USA). Data were analyzed by ANOVA and post hoc comparisons between group means analyzed using two-tailed unpaired t test. P values of less than 0.05 were considered statistically significant. Data are presented as mean ± SD.
Results
H NMR spectra and pattern recognition analysis of serum samples
Representative 1 H NMR spectra of the serum samples obtained from healthy subjects, BC and calculi patients are shown in Fig. 1 . Resonance assignments were performed based on two-dimensional NMR spectra (data not shown) and referred to previous works. 5, 13 OPLS-DA analysis shows that BC patients are distinctly separated from healthy subjects, and that the LBC group is also obviously distinguished from the HBC group (Fig. 2) . Similarly, BC patients are separated from calculi patients, while pre-TURBT group is clearly separated from post-TURBT along the PC2 direction. All the OPLS-DA models were validated with a 200-times permutation test, as the R2 and Q2 values calculated from the permuted data are lower than the original data in the validation plots and all Q2 intercepts the y-axis below zero (Fig. 3) .
Quantitative analysis of target metabolite levels in serum samples
The loading plot for the first two principal components of the 1.45 ± 0.81 a. The average age (mean ± SD), no significant age difference among groups indicated by one-way ANOVA. b. Tumor in the largest dimension (mean ± SD). OPLS-DA model displays decreased levels of isoleucine/leucine (Ile/Leu), tyrosine, phenylalanine, choline, lactate, glycine and citrate, as well as increased levels of V/LDL, glucose and acetoacetate in serum samples from BC patients compared with healthy subjects (data not shown). Comparisons of the metabolite levels among healthy, LBC and HBC groups are shown in Fig. 4 . Interestingly, the trend of changes in some metabolite levels (e.g. tyrosine, phenylalanine, glucose, glycine and lactate) was in accordance with the status of metastasis. In order to validate characteristic metabolites related to BC, we compared metabolite levels among BC, calculi patients and healthy subjects (Fig. S1 (Supporting Information)) , and also among pre-TURBT, post-TURBT patients and healthy subjects (Fig. S2 (Supporting Information)) . Compared with those in calculi patients, serum levels of metabolites in BC patients, including tyrosine, phenylalanine, glucose and V/LDL, exhibited the same trend of changes. Especially, serum levels of some metabolites in post-TURBT patients were recovered close to those in healthy subjects.
Discussion
Like most other cancers, tumorigenesis in BC patients is attributable to genetic changes in target cells, which result in malignant transformation. 15 This process might be accompanied by a series of metabolic events that stimulate cells to multiply or become aggressive. 16 Elucidation of metabolic changes occurring in the pathogenic process of BC could be helpful for exploring novel biomarkers for the diagnosis and surveillance of the disease, and for developing a new generation of anti-cancer drugs. In the present study, we compared serum metabolic profiles among LBC patients, HBC patients, and healthy subjects. Furthermore, to determine characteristic metabolites related to BC patients, we also compared serum metabolic profiles between BC patients and calculi patients, both sharing the similar symptom of hematuria. In addition, we also assessed changes of serum levels of metabolites between pre-TURBT and post-TURBT patients.
Metabolomic analysis of serum samples
The OPLS-DA scores plots exhibit that serum metabolic profiles of BC patients, calculi patients and healthy subjects are distinctly different. Especially, the LBC group is easily distinguished from the HBC group. Quantitative analysis of metabolites in serum samples identified significant changes of metabolite levels in BC patients compared with those either in calculi patients or in healthy subjects. Moreover, the metabolite Fig. 3 Validation of a 200 random permutation test for the supervised OPLS-DA models generated from serum samples of different groups described in Figs. 2A -2F , respectively: A, HBC, LBC patients and healthy subjects; B, HBC and LBC groups; C, calculi patients and healthy subjects; D, calculi patients and BC patients; E, pre-and post-TURBT patients and healthy subjects; F, pre-and post-TURBT patients. R2, green color; Q2, blue color. levels in post-TURBT BC patients were somewhat recovered to those in healthy subjects. These characteristic metabolites with distinct differences in serum levels among BC patients, calculi patients and healthy subjects, could be exploited as potential biomarkers for noninvasive diagnosis and treatment of BC. These metabolites are mostly amino acids, intermediates or products of glucose and lipids metabolism.
Amino acids metabolism
In the study, decreased levels of aromatic amino acids (tyrosine, phenylalanine) have been observed in serum samples from BC patients, compared to those levels from calculi patients. Previous works have demonstrated that levels of aromatic amino acids are closely associated with many diseases, such as phenylketonuria, 17 liver disease 18 and cancers. 19 Animal experiments showed that restriction of aromatic amino acids could result in decreased growth of tumor, and disapproval of aromatic amino acids would arrest tumor cells in the G0/G1 phase of cell cycle. 20 As a precursor of L-DOPA biosynthesis, the decreased level of tyrosine might be related to the transformation of L-DOPA in the body. Letellier et al. identified manifestly increased ratios of L-DOPA/tyrosine in plasma from melanoma patients with developing metastasis. 21 Davidson et al. also observed the elevated level of urinary dopamine in BC patients. 22 These works indicate that aromatic amino acids might play crucial roles in the pathogenic process of BC and could be further explored as potential biomarkers of BC.
Furthermore, levels of other amino acids are usually altered in serum samples from cancer patients. As one of nonessential amino acids, glycine is involved in production of DNA, phospholipids, collagen, and also in release of energy. With 1 H high-resolution magic angle spinning (HRMAS) NMR spectroscopy, Duarte et al. observed the decreased level of glycine in tumor samples from lung cancer patients, suggesting that glycine might be involved in altered metabolisms in tumor tissues. 23 In our study, we observed specifically altered glycine level in serum samples from BC patients, which is consistent with the results of the previous study.
As important branched-chain amino acids (BCAAs), Ile/Leu were detected with the decreased level in serum samples from LBC patients. Brosnan et al. indicated that BCAAs could exert a regulatory influence on proteolysis and thus could play important roles in building body organs. 24 Choudry et al. demonstrated that wound healing was enhanced with supplements of BCAAs. 25 However, the underlying mechanisms remain unclear.
Glucose metabolism
The turmorigenesis of neoplasms potentially involved in multiple molecular mechanisms, including altered glucose metabolism. 26 Stocks et al. showed that the elevated blood levels of glucose were linked with increased cancer risk. 27 Yeh et al. demonstrated that glucose and glycolysis-related genes participated in tumorigenesis of human colorectal cancers. 28 The levels of intermediates of glucose metabolism (citrate and lactate) were markedly lowered in serum samples from BC patients compared with those from healthy subjects, which might account for the accumulation of glucose observed in this study. The reduced levels of lactate was also observed in some types of cancers, such as osteosarcoma, 14 head and neck cancer. 29 However, these observations are strikingly different from the well known "Warburg effect" where, commonly, lactate levels are high in tumor tissues. 30 Glycolysis, the transformation of glucose to pyruvate, is a key step for the acquisition of ATP in all mammalian cells, including cancer tissues. 16 By immunohistochemical analysis of tissues samples from colorectal adenocarcinomas patients, Koukourakis demonstrated that cancer cells were dependent upon anaerobic metabolism with a high ability for glucose absorption and lactate extrusion. In contrast, the tumor-associated fibroblasts exhibited patterns involved in aerobic metabolism, lactate absorption, and lactate oxidation. 31 Koukourakis thereby proposed that, through organizing the regional fibroblasts and endothelial cells into a harmoniously collaborating metabolic domain, tumors survived and grew in the bodies. Indeed, many investigators stressed the unique molecular profile of tumor-associated fibroblasts. 32, 33 As a result, the unique behavior of glucose and lactate metabolism in BC patients in the study might be a cross section of metabolic events in multiple tissues, such as tumor cells and fibroblasts.
Lipids and ketone bodies metabolism
In serum samples from BC patients, we observed elevated trends of V/LDL compared with those from healthy and calculi subjects. Lipogenesis is the origin of membrane biosynthesis, which in turn is an essential requirement for cell growth and proliferation. 16 The previous work showed increased levels of glycerophospholipid and free fatty acids compositions in tumor tissues of BC animal models. 34 Through altered antioxidant status, the metabolic shift of lipogenesis might be one important factor for tumor development and growth in BC patients. 35 In addition, as important products of lipids metabolism, ketone bodies (e.g. acetoacetate) were observed with elevated serum levels in BC patients, indicative of enhanced lipogenesis. Thus, the elevated serum levels of lipids in BC patients could also be explored as potential indicators of BC.
Summarily, compared with calculi patients and healthy subjects, BC patients show a distinct signature of altered serum metabolite levels, indicative of specifically disrupted metabolic pathways of aromatic amino acid, glycolysis, citrate cycle, and lipogenesis metabolism (an accumulation of lipids and ketone bodies). The alteration trends in some metabolite levels (e.g. glucose, tyrosine and phenylalanine) is closely related to the status of metastasis, suggesting that these characteristic metabolites might play vital roles in the pathogenic process of BC and might provide new candidates for invasive detection and surveillance of BC. Our work substantiates once more the merit and strength of metabolomic analysis in areas of cancer research.
